The global impact of Precision Medicine Group.
As it happens.
Impact, observations, and insights on the evolving healthcare landscape.
This ON24 webinar will discuss how cell and gene therapies can be justifiably priced at different levels. We will explore just how high they can extend and also how we can collectively ensure that patients can access these innovations when they are needed. This discussion will be led by David Carr: Senior Director, Global Pricing and Market Access (PRECISIONadvisors), Richard Macaulay: SVP, Global Pricing and Market Access (PRECISIONadvisors).
Gene therapies offer hope for patients with severe genetic diseases by providing long-term benefits and even cures. However, the challenges of evaluating the long-term benefits of these therapies from a payer perspective are considerable. This white paper by PRECISIONadvisors highlights the shift of gene therapy research into more prevalent diseases, and outlines how manufacturers and payers can co—create evidence requirements and models to optimize launch success and sustainability.
Since the first gene therapy procedure more than 30 years ago, the field has seen significant advances and development, but also setbacks and issues. What is the future direction for gene therapies? Precision’s Phil Cyr, Richard Macaulay and Andy Kinley identify three future trends and how they might impact safety, manufacturing development, and reimbursement and payment.
Precision will be at this year’s Meeting on the Med, April 12-14, 2023, in Barcelona, Spain. Connect with our team of experts as they lead meaningful presentations and discussions throughout this event providing insights into the clinical development, manufacturing, and commercialization for cell and gene therapies.
Connect with our Advanced Therapy experts
You can register for Meeting on the Med below:
Over the last couple of years, we have witnessed the tremendous potential of adeno-associated virus (AAV)-based gene therapies. However, there have been a few high-profile safety issues that have occurred, including deaths associated with AAV vector gene therapies that have raised safety concerns among the public and regulators. Don’t miss this great primer on AAV-based gene therapies by Precision’s Deb Phippard and Phil Cyr, including basic background on the vectors, safety concerns, strategies to mitigate safety issues, and recent FDA safety meetings.
Precision will be at this year’s Gene Therapy for Rare Disorders on March 20-23, 2023, in Boston, MA. Connect with our team of experts as they lead meaningful presentations and discussions throughout this event providing insights into the clinical development, manufacturing, and commercialization for gene therapies.
Speaking Engagements
Detailed descriptions for each speaking engagement are included below.
Connect with our Advanced Therapy experts
—
Plenary Speaking Position: Successfully Launching a Gene Therapy with Cynthia Pussinen & Dave Lennon
Precision ADVANCE | March 21, 2023, 8:30 – 9AM ET
Speakers:
Panel Discussion: Current Trends in Technical Operations for Rare Disorders
Project Farma | March 21, 2023, 10:45-11:15AM ET
Speakers:
Panel Discussion: Manufacturing Track: Capacity versus Capability – Moving Towards Innovative Manufacturing Processes
Project Farma | March 21, 2023, 11:15 – 11:45AM ET
After record-setting milestones in fundraising over the past two years, the advanced therapy investment landscape is experiencing a natural correction. Precision’s Anshul Mangal and Dr. James M. Wilson outline in this The Medicine Maker article how industry leaders can ensure the advancement of innovative treatments for patients with #rarediseases by consolidating investments and prioritizing partnerships with patient advocacy organizations.
New study demonstrates the feasibility of systematically integrating long-term survival estimates obtained from a formal expert elicitation study with empirical clinical trial data through a case study.
Sponsored by Precision ADVANCE, this Endpoints webinar will convene leading advanced therapy experts to discuss the future of CGTx clinical development. This discussion will be moderated by Teresa Pokladowski: Regional VP, Clinical Business Solutions (Precision for Medicine), and include insights from Kinnari Patel: President & COO (Rocket Pharmaceuticals), Suma Krishnan: Founder & President (Kystal Biotech), Dawn Buchanan: VP Clinical Operations (AffyImmune), and Ramona Repaczki-Jones: Executive Director, Commercial Treatment Center Operations, Cell Therapy (lovance Biotherapeutics, Inc).
The cell and gene therapy (CGTx) sector has flourished in recent years due to continued investor confidence. However, the present downturn in public markets has negatively affected that confidence, raising questions about the sector’s prospects for 2023 and beyond.
This white paper is based on a panel discussion at the Cell & Gene Meeting on the Mesa (October 11, 2022), sponsored by Precision ADVANCE, focusing on the future of advanced therapies. The panel included insights from the following industry leaders: